Open-to-Accrual Therapeutic Trials


Melanoma and Cutaneous Oncology

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

EA6141 ClinicalTrials.gov: NCT02339571

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma S. Ghamande Inquiries Melanoma II/III

EA6134 ClinicalTrials.gov: NCT02224781

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma S. Ghamande Inquiries Melanoma III